Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

55.39
+0.74001.35%
Pre-market: 55.700.3100+0.56%06:06 EDT
Volume:1.37M
Turnover:75.27M
Market Cap:8.48B
PE:20.00
High:55.41
Open:54.36
Low:54.01
Close:54.65
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:0.92
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:14.04
PE(LYR):20.00

Loading ...

TG Therapeutics Down over 11%, on Pace for Largest Percent Decrease Since August 2025

Dow Jones
·
Aug 04

TG Therapeutics falls -10.6%

TIPRANKS
·
Aug 04

Movement Alert|TG Therapeutics Falls 5.35% in Regular Trading, Q2 EPS Misses Estimates by 85%

Market Focus
·
Aug 03

Stock Track | TG Therapeutics Plummets 7% in Intraday Trading After Q2 Earnings Miss Overshadows Strong Revenue and Raised Guidance

Stock Track
·
Aug 03

TG Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03

Movement Alert|TG Therapeutics Falls 5.37% in Pre-Market Trading, Q2 EPS Misses Estimates by 85%

Market Focus
·
Aug 03

Stock Track | TG Therapeutics (TGTX) Plunges 5.37% in Pre-market After Q2 Earnings Miss, Despite Strong Revenue and Raised Guidance

Stock Track
·
Aug 03

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

Reuters
·
Aug 03

TG Therapeutics Q2 Product Revenue Rises 70% on Briumvi Sales

Reuters
·
Aug 03

Earnings Flash (TGTX) TG Therapeutics Posts Q2 EPS $0.05, vs. FactSet Est of $0.31

MT Newswires Live
·
Aug 03

TG Therapeutics Q2 Net Income Drops to $7.8 Million; Revenue Rises 70.26% to $240.3 Million

Reuters
·
Aug 03

TG Therapeutics Q2 EPS $0.05 Misses $0.33 Estimate, Sales $240.335M Beat $229.721M Estimate

Benzinga Earnings
·
Aug 03

TG Therapeutics Q2 EPS USD 0.05

THOMSON REUTERS
·
Aug 03

TG Therapeutics - Raises FY 2026 Total Global Revenue Target to About $950 Mln

THOMSON REUTERS
·
Aug 03

TG Therapeutics Q2 Operating Income USD 21.674 Million

THOMSON REUTERS
·
Aug 03

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

GlobeNewswire
·
Aug 03

TG Therapeutics is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jul 28

B. Riley Raises Price Target on TG Therapeutics to $86 From $55, Keeps Buy Rating

MT Newswires Live
·
Jul 27

TG Therapeutics Inc : B. Riley Raises Target Price to $86 from $55

THOMSON REUTERS
·
Jul 27